1. Academic Validation
  2. Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia

Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia

  • Br J Haematol. 2018 Sep;182(6):927-930. doi: 10.1111/bjh.14884.
Abraham M Varghese 1 Andy Rawstron 2 Darren Newton 3 Reuben M Tooze 3 Talha Munir 1 Marion Dickson 4 Gina M Doody 3 Peter Hillmen 1
Affiliations

Affiliations

  • 1 Department of Haematology, St. James's University Hospital, Leeds, UK.
  • 2 Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, UK.
  • 3 Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
  • 4 Immunoinflammation Therapy Area, GlaxoSmithKline, Stevenage, UK.
Figures
Products